Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mark Stephen Huberman, M.D.

Co-Author

This page shows the publications co-authored by Mark Huberman and Susumu Kobayashi.
Connection Strength

1.096
  1. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 06; 11(6):918-23.
    View in: PubMed
    Score: 0.168
  2. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51.
    View in: PubMed
    Score: 0.135
  3. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
    View in: PubMed
    Score: 0.101
  4. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
    View in: PubMed
    Score: 0.094
  5. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
    View in: PubMed
    Score: 0.092
  6. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277.
    View in: PubMed
    Score: 0.056
  7. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555.
    View in: PubMed
    Score: 0.050
  8. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95.
    View in: PubMed
    Score: 0.048
  9. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177.
    View in: PubMed
    Score: 0.046
  10. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21.
    View in: PubMed
    Score: 0.045
  11. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883.
    View in: PubMed
    Score: 0.045
  12. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22.
    View in: PubMed
    Score: 0.043
  13. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74.
    View in: PubMed
    Score: 0.041
  14. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9.
    View in: PubMed
    Score: 0.039
  15. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
    View in: PubMed
    Score: 0.036
  16. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62.
    View in: PubMed
    Score: 0.031
  17. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.